Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Barrow
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 106
- Beta
- 2.24
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 14.31
Financials
Net Income
$-158.99MEBITDA
$-157.75MFree Cash Flow
$-52.78MEPS (diluted)
$-1.44Shares Outstanding (diluted)
110.68M+71016.8%Operating Expenses
$75.08MCash & Debt
$1.08BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-183.79M | $-2.06 |
| 2024 | $0.00 | $-108.68M | $-1.54 |
| 2023 | $0.00 | $-95.73M | $-2.44 |
| 2022 | $0.00 | $-56.80M | $-1.53 |
| 2021 | $0.00 | $-93.04M | $-3.40 |
| 2020 | $0.00 | $-34.10M | $-1.92 |
| 2019 | $0.00 | $-1.12M | $-2.94 |
| 2018 | $0.00 | $-857.9K | $-2.74 |
| 2017 | $0.00 | $-1.23M | $-4.85 |
| 2016 | $0.00 | $-179.9K | $-2.24 |
| 2015 | $0.00 | $-92.7K | $-1.17 |
Valuation
DFTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-76.92%Social Signal Score
Mentions (17)
- Newsbusinesswire.com·7d ago·Negative
Definium Therapeutics Announces New Employee Inducement Grants NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Co…
View source ↗ - Newsmarketbeat.com·12d ago·Positive
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression Definium Therapeutics NASDAQ: DFTX Chief Medical Officer Dan Karlin said the company's recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, following a single treatment, with longer-term open-label portions of the studies still underway.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, adding to positive pivotal-study results previously reported in GAD and major depressive disorder.
View source ↗ - Newszacks.com·20d ago·Neutral
Definium Reports Second Phase III Success in Anxiety Disorder Program DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
View source ↗ - News (RSS)seekingalpha·21d ago·Positive
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript
View source ↗ - News (RSS)zerohedge·21d ago·Neutral
…cquire the insurance brokerage firm. Corning (GLW) falls 9% after entering into a $2 billion equity distribution agreement with Goldman Sachs. Definium Therapeutics (DFTX) rises 16% after the company announced that its Phase 3 Panorama study met its primary and key secondary efficacy endpoints. Hewlett Packard Enterprise (HPE) falls 7% after Evercore ISI downgraded the company to inline from outperform, citing valuation in the wake of recent strength. Olema Pharmaceuticals (OLMA) falls 9% after …
View source ↗ - Newsbenzinga.com·21d ago·Neutral
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy' Definium Therapeutics Inc. (NASDAQ:DFTX) on Monday released topline results from Panorama, its second Phase 3 study evaluating DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD).
View source ↗ - News (RSS)financialpost·22d ago·Negative
Definium Therapeutics Announces New Employee Inducement Grants NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 56,650 common shares […]
View source ↗ - News (RSS)investing·22d ago·Neutral
Definium to present phase 3 anxiety disorder trial results Monday
View source ↗ - News (RSS)financialpost·22d ago·Neutral
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 Company to host webcast tomorrow at 8:00 a.m. EDT NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to […
View source ↗ - News (RSS)seekingalpha·31d ago·Positive
Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript
View source ↗ - Newsbusinesswire.com·41d ago·Neutral
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences and events: Stifel Hosted We…
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
Definium Therapeutics' DT120 Meets Phase III Goals in GAD Study Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The company said the trial met its primary endpoint and all key secondary endpoints, showing rapid and durable improvements in anxiety symptoms through 12 weeks.
View source ↗ - News (RSS)seekingalpha·54d ago·Positive
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript
View source ↗ - Newsbenzinga.com·54d ago·Neutral
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar' Late-stage clinical biopharmaceutical firm Definium Therapeutics, Inc. (NASDAQ:DFTX) has announced highly encouraging topline data from its Voyage trial.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.54 per share
Typical surprise -31.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.44 vs $-0.54miss
- Thu, May 7$-0.71 vs $-0.47miss
- Thu, Feb 26$-0.51 vs $-0.48miss
- Thu, Nov 6$-0.78 vs $-0.52miss
- Thu, Jul 31$-0.50 vs $-0.38miss
- Thu, May 8$-0.35 vs $-0.36beat
Estimates and results for DFTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DFTX officers and directors.
- Bought
- $45k
- Sold
- $8.7m
4 trades
38 trades
- Karlin Danielsold
- Barrow Robertsold
- Wiley Matthew T.sold
- Sullivan Marksold
- Roberts Brandisold
- Barrow Robertsold
- Sullivan Marksold
- Roberts Brandisold
58 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DFTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.